About vaccines

Suoja on erinomainen vakavaa koronatautia vastaan. //3.9.2021

A new cohort study comparing immune responses among vaccinated elderly persons and healthcare workers has been conducted. // 2.9.2021 The authors of the current study indicated a significant waning of immune responses induced via COVID-19 vaccination in the elderly. However, neutralizing capacity was still detected after six months of initial vaccination in the younger group of HCWs. This study showed a significant reduction in immunogenicity markers in the elderly six months post-vaccination. It also provided evidence that a two-dose vaccination regimen induces a less stable immune response in the elderly group as compared to younger groups.

Nature Reviews Neurology - Multiple sclerosis relapses not associated with mRNA COVID-19... // 2.9.2021

A recent US study, currently available on bioRxiv* preprint server, implies that vaccination with bacille Calmette-Guérin (BCG) can limit the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by targeting innate immune pathways and could thus be used as a platform for pinpointing early immunologic events affecting the outcome of coronavirus disease (COVID-19). //1.9.2021

This study reports an interim analysis of safety surveillance data of 23 serious outcomes following vaccination with 1 of the mRNA COVID-19 vaccines based on comprehensive health records from a large US population. //3.9.2021

To minimise SARS-CoV-2 infection, at-risk populations must be targeted in efforts to boost vaccine effectiveness and infection control measures. // 1.9.2021

Nenäsumutteena annosteltavaa koronavirusrokotetta on kehitetty antamaan parempi suoja esimerkiksi delta- ja uudempaa delta plus -muunnoksia vastaan. //1.9.2021

Scientists from the USA and Canada have recently demonstrated that the dynamics of antibody response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) vaccines are different. //31.8.2021

COVID-19 shots may not always prevent infections, but for now, they are keeping the vast majority of vaccinated people out of the hospital. //31.8.2021

A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals. // 31.8.2021

A recent study conducted by a team of US-based scientists has revealed that unvaccinated individuals are 17-times more likely to be hospitalized due to severe coronavirus disease 2019 (COVID-19) compared to those vaccinated against the disease. // 31.8.2021

In a review paper published in the journal Nature Reviews, researchers from Carnegie Mellon University and the University of Pennsylvania have described the underlying technologies for mRNA vaccines and their future prospects with improved delivery systems and applications in diseases beyond the ongoing COVID-19 pandemic. // 31.8.2021

A new study from Israel suggests immunity gained after recovering from a previous COVID-19 infection is more protective against the new Delta variant than vaccine-induced immunity. //30.8.2021 A lot of limitations

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. // 30.8.2021

A deep look into a nationwide mass vaccination setting in Israel revealed that the BNT162b2 (Pfizer–BioNTech) vaccine is not linked with an elevated risk of a majority of the adverse events under study, with the exception of myocarditis. // 30.8.2021 Certain unexpected effects were also observed, as Pfizer–BioNTech vaccine appears to offers a degree of protection against conditions such as intracranial hemorrhage and anemia, possibly by halting SARS-CoV-2 infection, which is a known risk factor for such events.

Now, a new study published on the medRxiv* preprint server focused on determining the effectiveness of the BNT162b2, ChAdOx1, and mRNA-1273 vaccines by conducting SARS-CoV-2 PCR-positive tests. //26.8.2021 The authors of this study stated that even though SARS-CoV-2 vaccination reduces new infections, the effectiveness in lowering the viral load against the Delta strain was found to be reduced.

A study suggests that the risk of clotting disorders appears to be significantly higher with COVID-19 infection compared to vaccination. //27.8.2021

Background The alpha and delta SARS-CoV-2 variants have been responsible for major recent waves of COVID-19 despite increasing vaccination rates. The reasons for the increased transmissibility of these variants and for the reduced transmissibility of vaccine breakthrough infections are unclear. // 25.8.2021 Viral concentrations do not fully explain the differences in infectiousness between SARS-CoV-2 variants, and mitigation measures are needed to limit transmission from vaccinated individuals.

COVID-19 vaccine effectiveness, reinfection, and hospitalization in fully, partially, and unvaccinated people during the Delta variant in Los Angeles County, California. — Los Angeles County, California, May 1–July 25, 2021

The study of over 40,000 Covid-19 cases in Los Angeles County also found that unvaccinated people were nearly five times more likely to be infected. //25.8.2021

Original Article from The New England Journal of Medicine — Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting // 25.8.2021

A new study evaluates the new COVID-19 policy implemented in NSW. //25.8.2021 In conclusion, the authors emphasize the effectiveness of robust public health and social restrictions in reducing COVID-19 cases and hospitalizations, as compared to solely relying on an increase in vaccine rollout.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have proven effective at preventing COVID-19-related mortality and illness. Since no vaccine is 100% effective, breakthrough infections are likely to occur. // 25.8.2021 In conclusion, the authors emphasize the effectiveness of robust public health and social restrictions in reducing COVID-19 cases and hospitalizations, as compared to solely relying on an increase in vaccine rollout.

Nature - Scientists are trying to understand why a small number of people develop a mysterious clotting disorder after receiving a COVID jab. //24.8.2021

A study estimated that COVID-19 vaccinations prevented nearly 140,000 deaths in the U.S. by May 2021. //24.8.2021

A new preprint on the medRxiv server supports the role of vaccination in reducing the rate of symptomatic coronavirus disease 2019 (COVID-19). // 24.8.2021

In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests. //24.8.2021

The new CDC study also found that unvaccinated people were nearly five times more likely to be infected with Covid than vaccinated people. //24.8.2021

Nature - Massive UK study of COVID-19 cases shows that people who are jabbed have good immunity at first, but quickly become more vulnerable to the fast-spreading Delta variant. //24.8.2021 92% effective at keeping people from developing a high viral load

Scientists predict the COVID-19 pandemic is on its way to becoming endemic. The rising spread of COVID-19 variants such as Delta has helped infect unvaccinated and some vaccinated individuals. COVID-19 vaccines continue to be the best way to protect against severe illness and death, but there may be a need for vaccines to protect against a specific variant. //23.8.2021